03:21 PM EDT, 05/07/2024 (MT Newswires) -- Novo Nordisk ( NVO ) is seeking more time to respond to US Sen. Bernie Sanders' queries over the prices of diabetes medication Ozempic and weight loss drug Wegovy, Bloomberg reported Tuesday.

Sanders, the chair of the Senate Health, Education, Labor and Pensions committee, last month asked Novo to respond to questions on cost and manufacturing of the drugs by Wednesday.

Neither Novo nor Sanders' office immediately responded to MT Newswires' requests for comment.

The company shares were up 2.5% in recent trading.

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

Price: 127.76, Change: +3.17, Percent Change: +2.54